US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026

January 2021 | 600 pages | ID: U4B2C9439690EN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

"US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:

• US Prostate Cancer Drug Market Opportunity: > US$ 4 Billion
• Comprehensive Clinical Insight On 25 FDA Approved Prostate Cancer Drugs
• Drug Dosage, Patent, Price, Patent Insight
• Insight On 222 Prostate Cancer Drugs In Clinical Trials
• Clinical Trial Overview by Biomarker, Drug class, Formulation, Organization, Patient Segment & Phase
• 600 Page Analysis On Clinical & Commercial Market Trends

US pharmaceutical market has observed several biggest breakthroughs in the past few years. The researchers in the country have opened hundreds of novel paths such as diagnosing assays, drugs and therapies for the patients suffering from early or advanced stage prostate cancer. The entire momentum created by the oncology researchers with the help of strong backbone of the government and the regulatory bodies, has made the country’s prostate cancer therapeutics market share a large percentage of the total cancer market. The association of the US oncology researchers with high promising tools developed by UCLA researchers, bio-pharmaceutical companies and other elite educational institutes have ultimately led to normalize the condition that was prevailing in the country for high prostate cancer cases and mortality rate. More willingly, the arrival of hundreds of therapeutic approaches for the prostate cancer patients have inclined the entire market towards astounding results, leading to a phase where the market is ready to thrive the next-generation of the market.

The healthcare applications related with the market drugs and therapies is stemming the entire treatment regimen towards solving the unmet needs of the patients and gradually cause an upregulation in the market share and size. In general term, the market healthcare applications is on the edge of providing the worldwide oncology researchers to invest into the US market and observe hundreds of trending opportunities with respect to investments. In the past few years, it can be observed that the overall reliability of the prostate cancer patients on the available drugs and therapies has increased, leading to the phase where clinical pipeline of the market has received unlimited approvals and launches by the regulatory bodies. In addition to this, the association of the entire market with numerous investments on their back has led to the profound identification and development of potential clinical products having numerous healthcare applications such as no major side effects and very less chances of cancer recurrence. All this have eventually made the country the biggest supporter of the global prostate cancer therapeutics market.

US prostate cancer therapeutics market in few years has moved towards remarkable progress. With respect to understanding the entire mechanism of action of the cancer at early as well as advanced stage have completely shifted the market towards paradigmatic development of immunotherapies, several different chemotherapeutic agents and small molecule cancer drugs. In addition to this, the novel promises made by the government in reimbursing 100% treatment cost for prostate cancer has also modified the entire market towards novel version. The clinical management associated with the market such as teams offering novel healthcare strategies are also inclining the market towards splendid growth and a memento for superior treatment facilities.

As per report findings, the pace of the prostate cancer market is accelerating at a high rate. The arrival of cluster of innovative drugs and therapies introduced in the patients as single therapy or in combination have also oriented millions of prostate cancer patients worldwide towards adopting the treatment regimen developed by the US oncology researchers. The overall clinical landscape developed by the researchers in few years of time has ensured appropriate care while ensuring the overall survival rate and complete response in the patients. The entire market of spiraling research and development associated with prostate cancer is believed to fragment the market towards more promising opportunities. The positive-outcomes for every drug and therapy available is believed to line up the market towards evolution and thus, towards a treatment paradigm capable of offering highest return to the prostate cancer patients in the US as well as in the world.

Contents

1. US PROSTATE CANCER DRUG MARKET OVERVIEW

2. APPROVED PROSTATE CANCER DRUGS INSIGHT BY CLASS

2.1 Chemotherapeutic Drugs
2.2 Hormonal Therapy
2.3 Immunotherapy
  2.3.1 Cancer Vaccines
  2.3.2 Immune Checkpoint Inhibitors
2.4 PARP Inhibitors

3. NOVEL EMERGING THERAPIES IN PROSTATE CANCER

3.1 Bi-Specific T-Cell Engagers (BiTE)
3.2 Small Molecule Prostate Cancer Drugs
3.3 Radioligand Therapy
3.4 Antibody Drug Conjugates

4. US PROSTATE CANCER DRUGS: GENERIC & BIOSIMILAR LANDSCAPE

4.1 Current Scenario & Price Differential
4.2 Reimbursement Scenario

5. ANTI-ANDROGEN DRUGS FOR PROSTATE CANCER – US MARKET AVAILABILITY, DOSAGE, PATENT & PRICE INSIGHT

5.1 Apalutamide (Erleada)
5.2 Xtandi (Enzalutamide)
5.3 Darolutamide (Nubeqa)
5.4 Abiraterone (Zytiga)
5.5 Bicalutamide (Casodex)
5.6 Nilutamide (Nilandron)
5.7 Flutamide

6. PARP INHIBITORS FOR PROSTATE CANCER – US MARKET AVAILABILITY, DOSAGE, PATENT & PRICEINSIGHT

6.1 Rucaparib (Rubraca)
6.2 Olaparib (Lynparza)

7. RADIOACTIVE PHARMACEUTICAL AGENTS FOR PROSTATE CANCER – US MARKET AVAILABILITY, DOSAGE & PRICE INSIGHT

7.1 Radium 223 Dichloride (Xofigo)
7.2 Fluciclovine 18F (Axumin)

8. MITOTIC INHIBITORS FOR PROSTATE CANCER - US MARKET AVAILABILITY, DOSAGE, PRICE & PATENT INSIGHT

8.1 Cabazitaxel (Jevtana)
8.2 Docetaxel (Taxotere)

9. IMMUNOTHERAPEUTICS FOR PROSTATE CANCER – US MARKET AVAILABILITY, DOSAGE & PRICE INSIGHT

9.1 Provenge (Sipuleucel – T)
9.2 Capromab Pendetide (ProstaScint)

10. GONADOTROPIN RELEASING HORMONES DRUGS FOR PROSTATE CANCER - US MARKET AVAILABILITY, DOSAGE & PRICE INSIGHT

10.1 Triptorelin (Trelstar)
10.2 Leuprolide
10.3 Goserelin (Zoladex)
10.4 Histrelin Acetate Subcutaneous Implant (Supprelin LA/Vantas)
10.5 Degarelix (Firmagon/Gonax)

11. ESTROGENS FOR PROSTATE CANCER - US MARKET AVAILABILITY, DOSAGE & PRICE INSIGHT

11.1 Estradiol
11.2 Conjugated Estrogen

12. OTHER PROSTATE CANCER TARGETING THERAPEUTICS - US MARKET AVAILABILITY, DOSAGE & PRICE INSIGHT

12.1 Estramustine (Emcyt)
12.2 Mitoxantrone (Novantrone)
12.3 Cyclophosphamide
12.4 Capecitabine (Xeloda)
12.5 Zoledronic Acid (Zometa/Reclast)

13. US - PROSTATE CANCER DRUG CLINICAL TRIALS OVERVIEW

13.1 By Biomarket
13.2 By Drug Class
13.3 By Formulation
13.4 By Organization
13.5 By Patient Segment
13.6 By Phase

14. US - PROSTATE CANCER DRUGS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-0
14.6 Phase-I
14.7 Phase-I/II
14.8 Phase-II
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. US - MARKETED PROSTATE CANCER DRUGS CLINICAL INSIGHT

16. US PROSTATE CANCER MARKET DYNAMICS

16.1 Market Drivers
16.2 Market Challenges

17. US PROSTATE CANCER MARKET FUTURE PROSPECTS

18. COMPITITIVE LANDSCAPE

18.1 AbbVie
18.2 Accord Healthcare
18.3 Allergan
18.4 Amgen
18.5 Astellas Pharma
18.6 AstraZeneca plc
18.7 Bayer
18.8 Bristol Mayer Squibb
18.9 Clovis Oncology
18.10 Dendreon
18.11 Genentech
18.12 Jassen Pharmaceuticals
18.13 Merck
18.14 Mylan
18.15 Novartis AG
18.16 Pfizer
18.17 Roche
18.18 Sanofi
18.19 Sun Pharma
18.20 Teva Pharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 1-1: US - Estimated Cases & Deaths from Prostate Cancer, 2020 &2040
Figure 1-2: US - Prostate Cancer Drug Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-1: Hormonal Therpay Targets in Prostate Cancer
Figure 2-2: Provenge – Mechanism of Action
Figure 2-3: Provenge in Clinical Trials
Figure 2-4: Keytruda – Mode of Action
Figure 2-5: Immune Checkpoint Inhibitors in Clinical Trial
Figure 2-6: PARP Inhibitors- Mode of Action

Figure 4-1: Prostate Cancer – Cost of Treatment (US$)
Figure 4-2: Taxotere & Docetaxel – Cost of Intravenous Solution Per Unit (US$)
Figure 4-3: Zytiga & Abiraterone – Cost of Oral Tablet per unit (US$)
Figure 4-4: Lynpraza – Total Cost of Treatment & Reimbursement Cost (US$)
Figure 4-5: Lynpraza - In Pocket Cost & Out Pocket Cost (%)

Figure 5-1: Erleada – Aragon related Patent Issue & expiration Year
Figure 5-2: Erleada – University of California related Patent Issue & Expiration Year
Figure 5-3: Erleada – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-4: Erleada – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021
Figure 5-5: Xtandi – FDA Approval Year by Indication
Figure 5-6: Xtandi – Patent Issue & Expiration Year
Figure 5-7: Xtandi – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-8: Xtandi – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021
Figure 5-9: Xtandi – Cost of Single Capsule & Daily Treatment Cost (US$), January’2021
Figure 5-10: Nubeqa – Aragon Related Patent Issue & Expiration Year

Figure 5-11: Nubeqa – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-12: Nubeqa – Price of Single Tablet & Daily Treatment Cost (US$), January’2021
Figure 5-13: Zytiga – FDA Approval by Indication
Figure 5-14: Zytiga – FDA approval & First generic Approval Year
Figure 5-15: Zytiga – Price for Supply of 120 tablets & Price Per Unit Tablet of 250mg (US$), January’2021
Figure 5-16: Zytiga – Price for Supply of 60 tablets & Price Per Unit Tablet of 500mg (US$), January’2021
Figure 5-17: Generic Abiraterone – Price for Supply of 30 Tablets & 120 tablets & Price Per Unit Tablet of 250mg (US$), January’2021
Figure 5-18: Abiraterone – Daily Treatment Cost Branded v/s Generic (US$), January’2021
Figure 5-19: Casodex – FDA Approval & Patent Expiration Year
Figure 5-20: Casodax – Price for 30 Tablets Supply & Price Per Unit Tablet (US$), January’2021
Figure 5-21: Generic Bicalutamide – Price for 30 Tablets Supply & Price Per Unit Tablet (US$), January’2021
Figure 5-22: Nilandrone – FDA Approval & First Generic Approval Year
Figure 5-23: Eloxatin – FDA Approval Year by Strength of Tablet
Figure 5-24: Nilandrone – Price for 30 Tablet Supply & Price Per Unit Tablet of 150mg (US$), January’2021
Figure 5-25: Nilandrone – Recommended Dose for Prostate Cancer Treatment (mg/day), January’2021
Figure 5-26: Flutamide – Price for 180 Capsule Supply & Price per Unit Capsule of 125mg (US$), January’2021
Figure 5-27: Flutamide – Daily & Monthly Treatment Cost of Prostate Cancer (US$), January’2021

Figure 6-1: Rubraca – FDA Approval Year by Indication
Figure 6-2: Rubraca – FDA Approval Year by Strength
Figure 6-3: Rubraca - Number of Patents by Assignee
Figure 6-4: Rubraca - Patents Expiration Year by Assignee

Figure 6-5: Rubraca – Price for a Supply of 60 Tablets & Price Per Unit Tablet (US$), January’2021
Figure 6-6: Rubraca – Recommended Initial & Reduced Dose (mg/twice daily)
Figure 6-7: US - Rubraca Global Sales Value (US$ Million), 2018 & 2019
Figure 6-8: US - Rubraca Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 6-9: US - Rubraca Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 6-10: Lynparza – FDA Approval Year by Indication
Figure 6-11: Lynparza - Number of Patent Issued by Assignee Name
Figure 6-12: Lynparza – Patent Expiration Year by Assignee
Figure 6-13: Lynparza – Price for 60 & 120 Tablet Supply & Price Per Unit Tablet (US$), Janauary’2021
Figure 6-14: Lynparza – Recommended Dose & Dose after Reduction (mg/day)
Figure 6-15: US - Lynparza Annual Sales Value (US$ Million), 2017 - 2019
Figure 6-16: Lynparza - Annual Sales Value by Region (US$ Million), 2019
Figure 6-17: Lynparza – Annual Sales Value by Region (%), 2019
Figure 6-18: US - Lynparza Quarterly Sales Value (US$ Million), 2019
Figure 6-19: US - Lynparza Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 7-1: Xofigo – Patent Issue & Expiration Year
Figure 7-2: Xofigo – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 7-3: Xofigo – Cost of Single Treatment Cycle & Full Treatment (Weeks)
Figure 7-4: Axumin – Number of Patents by Assignee
Figure 7-5: Axumin – Patent Expiration Year by Assignee

Figure 8-1: Jevtana – Patent Issue & Expiration Year
Figure 8-2: Jevtana – Price for 1.5ml Supply & Price per unit of Intravenous Solution (US$), January’2021
Figure 8-3: Jevtana – Recommended & Incremented Dose of Jevtana for Prostate Cancer (mg/m2/3 weeks)
Figure 8-4: Taxotere – FDA Approval year by Strength
Figure 8-5: Taxotere – First Generic Approval year by Strength
Figure 8-6: Docetaxel – FDA Approval year by Companies
Figure 8-7: Taxotere – Price for 4ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$, January’2021

Figure 8-8: Docetaxel – Average Price for 2ml, 8ml & 16ml Supply 10mg/ml Intravenous Solution (US$, January’2021
Figure 8-9: Docetaxel – Average Price for 1ml, 4ml, 8ml & 10ml Supply 20mg/ml Intravenous Solution (US$, January’2021
Figure 8-10: Docetaxel – Minimum & Maximum Recommended Dose (mg/m2/3 weeks)

Figure 9-1: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January’2021
Figure 9-2: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January’2021

Figure 10-1: Trelstar – FDA Approval Year by Dose Strength of Injection
Figure 10-2: Trelstar – Patent Issue & Expiration Year
Figure 10-3: Trelstar – Price for Various Supplies of Intravenous Powder (US$), January’2021
Figure 10-4: Trelstar – Recommended dose by Duration of Treatment Cycle (mg)
Figure 10-5: Leuprolide – FDA approval Year by Brand Name
Figure 10-6: Lupron Depot – Patent Issue & Expiration Year
Figure 10-7: Eligard – Cost of Various Supplies of Subcutaneous Powder for Injection (US$), January’2021
Figure 10-8: Lupron – Cost of Various Supplies of Intramuscular Kit (US$), January’2021
Figure 10-9: Lupron – Cost of Various Supplies of Intramuscular Powder for Injection (US$), January’2021
Figure 10-10: Lutrate – Cost of Various Supplies of Intramuscular Powder for Injection (US$/GBP), January’2021
Figure 10-11: Generic Leuprolide – Average Single Day, Monthly & Annual Treatment Cost of Prostate Cancer (US$), January’2021
Figure 10-12: Leuprolide – Average Annual Treatment Cost Comparison of Branded v/s Generic (US$), January’2021
Figure 10-13: Zoladex – FDA Approval Year by Strength of Implant
Figure 10-14: Zoladex – Patent Issue & Expiration Year

Figure 10-15: Zoladex – Price for Single 3.6mg & 10.8mg Implant (US$), January’2021
Figure 10-16: Zoladex – Recommended dose by Duration of Treatment Cycle (mg)
Figure 10-17: Histrelin – FDA approval Year by Brand Name
Figure 10-18: Supprelin LA – FDA Approval Year by Brand Name
Figure 10-19: Histrelin – Price for Single 50mg Implant by Brand Name (US$), January’2021
Figure 10-20: Degarelix – FDA & PMDA Approval Year
Figure 10-21: Firmagon – Patent Issue & Expiration Year
Figure 10-22: Firmagon – Price for Single 80mg & 120mg Powder for Injection (US$), January’2021
Figure 10-23: Degarelix – Recommended Initial Dose & Maintenance Dose (mg/4weeks)

Figure 11-1: Estrace – Price for 100 Tablets Supply & Price Per Unit Tablet of 0.5mg & 1mg Dose (US$), January’2021
Figure 11-2: Estrace – Price for 100 Tablets Supply & Price Per Unit Tablet of 2mg Dose (US$), January’2021
Figure 11-3: Delestrogen – Price for 5ml Supply & Price per ml of 10mg/ml Intramuscular Solution (US$), January’2021
Figure 11-4: Delestrogen – Price for 5ml Supply & Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021
Figure 11-5: Delestrogen – Price for 5ml Supply & Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021
Figure 11-6: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 0.5mg Dose (US$), January’2021
Figure 11-7: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 1mg Dose (US$), January’2021
Figure 11-8: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 0.5mg Dose (US$), January’2021
Figure 11-9: Estradiol Valerate – Price for 5ml Supply & Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021
Figure 11-10: Estradiol Valerate– Price for 5ml Supply & Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021

Figure 11-11: Estradiol – Minimum & Maximum Oral Dose (mg/day), January’2021
Figure 11-12: Premarin – Price for 100 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), January’2021
Figure 11-13: Premarin – Price for 1000 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), January’2021
Figure 11-14: Premarin – Minimum & Maximum Oral Dose (mg/day), January’2021

Figure 12-1: Emcyt – Price for 100 Capsules Supply & Price per unit Capsule of 140mg Dose (US$), January’2021
Figure 12-2: Emcyt – Minimum & Maximum Daily Dose (mg/Kg/day)
Figure 12-3: Mitoxantrone – Price for 10 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-4: Mitoxantrone – Price for 12.5 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-5: Mitoxantrone – Price for 15 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-6: Mitoxantrone – Minimum & Maximum Dose (mg/m2)
Figure 12-7: Cyclophosphamide – Price for various Supplies of intravenous Powder for Injection (US$), January’2021
Figure 12-8: Cyclophosphamide – Price for various Supplies of 200mg/ml intravenous Solution for Injection (US$), January’2021
Figure 12-9: Cyclophosphamide – Price for 100 Capsule Supply of 25mg & 50mg Dose (US$), January’2021
Figure 12-10: Cyclophosphamide – Minimum & Maximum Dose as Single Agent (mg/Kg), January’2021
Figure 12-11: Xeloda – FDA Approval Year & First Generic Approval Year
Figure 12-12: Capecitabine – Price for 60 Tablet Supply & Price per unit of 150mg Branded & Generic tablet (US$), January’2021
Figure 12-13: Xeloda – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), January’2021
Figure 12-14: Capecitabine – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), January’2021
Figure 12-15: Capecitabine – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 12-16: Zometa – FDA Approval & First Generic Approval Year
Figure 12-17: Reclast – FDA Approval & First Generic Approval Year
Figure 12-18: Zometa – Price for 5ml Supply & Price per ml of Intravenous Solution (US$), January’2021
Figure 12-19: Reclast – Price for 10ml Supply & Price per ml of Intravenous Solution (US$), January’2021
Figure 12-20: Generic Zoledronic Acid – Price for 5ml and 200ml Supply of 4mg/ml Intravenous Solution (US$), January’2021
Figure 12-21: Generic Zoledronic Acid – Price for 100ml & Price per ml of 4mg/100ml Intravenous Solution (US$), January’2021
Figure 12-22: Generic Zoledronic Acid – Price for 100ml & Price per ml of 5mg/100ml Intravenous Solution (US$), January’2021

Figure 13-1: US - Number of Prostate Cancer Drugs in Clinical Trials by Biomarker, 2021 till 2026
Figure 13-2: US - Number of Protate Cancer Drugs in Clinical Trials by Drug Class, 2021 till 2026
Figure 13-3: US - Number of Prostate Cancer Drugs in Clinical Trials by Formulation, 2021 till 2026
Figure 13-4: US - Number of Prostate Cancer Drugs in Clinical Trials by Organization, 2021 till 2026
Figure 13-5: US - Number of Prostate Cancer Drugs in Clinical Trials by Patient Segment, 2021 till 2026
Figure 13-6: US - Number of Prostate Cancer Drugs in Clinical Trials by Phase, 2021 till 2026

COMPANIES MENTIONED

AbbVie
Accord Healthcare
Allergan
Amgen
Astellas Pharma
AstraZeneca plc
Bayer
Bristol Mayer Squibb
Clovis Oncology
Dendreon
Genentech
Jassen Pharmaceuticals
Merck
Mylan
Novartis AG
Pfizer
Roche
Sanofi
Sun Pharma
Teva Pharmaceuticals